Efficacy and Safety of Sphingosine 1-Phosphate Receptor Modulators for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

• Published in: Journal of clinical gastroenterology Vol. 58; no. 8; p. 753
• Main Authors: Mahmud, Omar, Fatimi, Asad Saulat, Mahar, Muhammad Umar, Jahangir, Arshia, Kashif, Aleena, Abbas, Manzar, Waljee, Akbar K, Berinstein, Jeffrey A
• Format: Journal Article
• Language: English
• Published: United States 01.09.2024
• Subjects: Colitis, Ulcerative - drug therapy; Humans; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Sphingosine 1 Phosphate Receptor Modulators - adverse effects; Sphingosine 1 Phosphate Receptor Modulators - therapeutic use; Sphingosine-1-Phosphate Receptors; Treatment Outcome
• DOI: 10.1097/MCG.0000000000002027

Sphingosine 1-phosphate receptor modulators (S1PRMs) are an effective treatment for ulcerative colitis (UC). This review summarizes all available randomized trial data on the efficacy and safety of S1PRM therapy. Multiple publication databases were systematically searched for randomized control trials (RCTs) of adults with moderate to severe UC treated with S1PRMs. Random effects meta-analysis was performed. The risk of bias was assessed using the Cochrane Risk-of-Bias 2 tool, and the overall quality of evidence was rated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. We identified 7 RCTs (1737 patients) involving the use of S1PRMs for moderate to severe UC. During induction, S1PRM therapy was efficacious when compared with placebo for clinical remission [RR: 2.65 (95% CI: 2.00, 3.53)], clinical response [RR: 1.68 (95% CI: 1.48, 1.91)], endoscopic improvement [RR: 2.17 (95% CI: 1.76, 2.68)], endoscopic normalization [RR: 2.56 (95% CI: 1.58, 3.83)], mucosal healing [RR: 2.88 (95% CI: 1.94, 4.26)], and histologic remission [RR: 2.42 (95% CI: 1.60, 3.66)]. Similar results were seen throughout the maintenance peroid, although fewer data were available to pool; notably, both sustained [RR: 3.57 (95% CI: 1.23, 10.35)] and steroid-free [RR: 2.92 (95% CI: 1.35, 6.33)] remission were significantly increased by S1PRM. There were no significant differences in adverse events [RR: 1.02 (95% CI: 0.90, 1.15)] and infections [RR: 1.15 (95% CI: 0.82, 1.60)] between S1PRM and placebo. Pooling of RCT data confirms that S1PRM therapy is both effective and safe for patients with moderate to severe UC.